A phase I study investigating the effect of ABT-751 given in combination with capecitabine, irinotecan and bevacizumab in advanced colorectal cancer patients

Trial Profile

A phase I study investigating the effect of ABT-751 given in combination with capecitabine, irinotecan and bevacizumab in advanced colorectal cancer patients

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2015

At a glance

  • Drugs ABT 751 (Primary) ; Bevacizumab; Capecitabine; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 Dec 2015 New trial record
    • 03 Dec 2015 Results published in the Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top